20 October 2017 - The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma.

Patients with the condition have limited treatment options and are currently offered docetaxel, paclitaxel and best supportive care.

Opdivo (nivolumab) was approved by the European Commission in to treat adults with locally advanced unresectable or urothelial carcinoma after failure of prior platinum-containing therapy in June, making it the only immuno-oncology agent available in the region for this type of bladder cancer.

Read Pharma Times article